Moderna Stock Jump Follows Cruise Ship Hantavirus Cases, Analysts Say Pandemic Risk Remains Low
Shares of Moderna climbed after reports of Hantavirus infections aboard the cruise ship MV Hondius, but Bernstein Global Research cautions that the event is unlikely to become a global pandemic. The firm left its Market-Perform rating and $45.00 price target intact, noting Moderna’s mRNA platform could be repurposed but that collaborations remain p…